Arrowhead Research Plummets By: MarketMinute.com Stock News March 24, 2014 at 18:55 PM EDT Arrowhead Research Corp. (Nasdaq: ARWR) began patient dosing in a Phase 2a clinical trial of ARC-520 to treat chronic hepatitis B but the stock price plummeted $3.33 to close at $17.37.